National trends in the treatment of Adult Diffuse Midline Gliomas: A Rare Clinical Scenario

Purpose: Diffuse midline gliomas (DMG) include all gliomas with a diffuse growth pattern occurring in midline structures of the brainstem. These tumors are classified as a WHO grade 4 with a mean survival of nine months following diagnosis. There is currently no standard of care for DMG and palliative radiation therapy has proven to extend survival by three months. Our current study aims to report trends and predictors of the overall survival of DMG.

Methodology: We searched the National Cancer Database for adult patients treated for DMG between 2004 -2020. Patients were required to have had primary radiation directed at the brain with or without concurrent chemotherapy. Univariable and multivariable Cox regressions were used to determine predictors of overall survival.

Results: Of the 131 patients meeting the inclusion criteria, 113 (86%) received radiation and chemotherapy. On multivariable cox regression, significant predictors of survival were charlson-deyo comorbidity index and race. Patients with a charlson-deyo score of 1 ha 2.72 times higher odds of mortality than those with a score of 0. Patients not identifying as white or black had 2.67 times higher odds of mortality than those identifying as white. The median survival for all patients was 19 months.

Conclusions: Despite being considered ineffective, chemotherapy is still administered in most adult patients diagnosed with DMG. Significant predictors of survival were charlson-deyo comorbidity index and race.

References: 1. López-Pérez CA, Franco-Mojica X, Villanueva-Gaona R, Díaz-Alba A, Rodríguez-Florido MA, Navarro VG. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity. J Neurooncol. 2022;158(3):369-378. doi:10.1007/s11060-022-04024-5
2. Zheng L, Gong J, Yu T, et al. Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases. The American Journal of Surgical Pathology. 2022;46(6):863. doi:10.1097/PAS.0000000000001897
3. Persson ML, Douglas AM, Alvaro F, et al. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. Neuro-Oncology. 2022;24(9):1408-1422. doi:10.1093/neuonc/noac117